Lexicon Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1995-01-01

Employees: 285

Market Cap: $621.7M

Website: http://www.lexpharma.com

Introduction: Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company...

Clinical Trials

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: 75 mg LX4211
Drug: 200 mg LX4211
Drug: 400 mg LX4211
Drug: Placebo

First Posted Date: 2011-06-20

Last Posted Date: 2014-10-31

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 299

Registration Number: NCT01376557

Locations: 🇺🇸
Lexicon Investigational Site, Virginia Beach, Virginia, United States

A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Schedule A
Drug: Schedule B
Drug: Schedule C
Drug: Schedule D
Drug: Schedule E

First Posted Date: 2011-04-13

Last Posted Date: 2011-05-19

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT01334242

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: 400 mg LX4211
Drug: 1000 mg metformin

First Posted Date: 2011-02-10

Last Posted Date: 2011-03-30

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT01292993

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: 300 mg LX4211 (150 mg tablets)
Drug: 300 mg LX4211 (50 mg tablets)
Drug: 300 mg LX4211 (liquid)

First Posted Date: 2010-08-26

Last Posted Date: 2011-03-30

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT01188863

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Phase 2

Completed

Conditions: Carcinoid Syndrome

Interventions: Drug: Telotristat etiprate

First Posted Date: 2010-04-15

Last Posted Date: 2019-03-15

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT01104415

Locations: 🇬🇧
Lexicon Investigational Site, Manchester, United Kingdom

Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LX4211 Low Dose
Drug: LX4211 High Dose
Drug: Placebo

First Posted Date: 2009-08-19

Last Posted Date: 2011-03-03

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT00962065

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: LX3305 low dose
Drug: LX3305 mid dose
Drug: LX3305 high dose
Drug: Placebo

First Posted Date: 2009-05-18

Last Posted Date: 2011-12-15

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 208

Registration Number: NCT00903383

Locations: 🇷🇸
Lexicon Investigational Site, Niska Banja, Serbia

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Phase 2

Completed

Conditions: Carcinoid Syndrome

Interventions: Drug: Telotristat etiprate
Drug: Octreotide LAR Depot
Drug: Placebo

First Posted Date: 2009-02-27

Last Posted Date: 2018-12-26

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT00853047

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Texas Oncology - Weslaco, Weslaco, Texas, United States
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States

and more 6 locations

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: LX3305
Drug: LX3305 Placebo
Drug: Methotrexate

First Posted Date: 2009-02-19

Last Posted Date: 2010-06-03

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT00847886

Locations: 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States

Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

Phase 2

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: LX1031 High Dose
Drug: LX1031 Low Dose
Drug: Placebo

First Posted Date: 2008-12-22

Last Posted Date: 2010-12-02

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 155

Registration Number: NCT00813098

Locations: 🇺🇸
Affiliated Clinical Research, Las Vegas, Nevada, United States
🇺🇸
Medoff Medical/Vital re:Search, Greensboro, North Carolina, United States
🇺🇸
Consultants for Clinical Research, Cincinnati, Ohio, United States

and more 33 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy